abstract
-
OBJECTIVES: To evaluate outcomes of patients achieving a post-treatment pathological stage of
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
Academic Article
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- November 2021
has subject area
- 1103 Clinical Sciences (FoR)
- Adult (MeSH)
- Aged (MeSH)
- Aged, 80 and over (MeSH)
- Antineoplastic Combined Chemotherapy Protocols (MeSH)
- Chemotherapy, Adjuvant (MeSH)
- Cisplatin (MeSH)
- Cystectomy (MeSH)
- Deoxycytidine (MeSH)
- Doxorubicin (MeSH)
- Female (MeSH)
- Gemcitabine (MeSH)
- Humans (MeSH)
- Internationality (MeSH)
- Kaplan-Meier Estimate (MeSH)
- Male (MeSH)
- Methotrexate (MeSH)
- Middle Aged (MeSH)
- Muscle, Smooth (MeSH)
- Neoadjuvant Therapy (MeSH)
- Neoplasm Invasiveness (MeSH)
- Neoplasm Metastasis (MeSH)
- Neoplasm Recurrence, Local (MeSH)
- Neoplasm Staging (MeSH)
- Proportional Hazards Models (MeSH)
- Risk Factors (MeSH)
- Time Factors (MeSH)
- Urinary Bladder (MeSH)
- Urinary Bladder Neoplasms (MeSH)
- Urology & Nephrology (Science Metrix)
- Vinblastine (MeSH)
published in
- BJU International Journal